



16 January 2026

Completion of A\$11 Million Capital Raise and Receipt of Cornerstone Investment

Vitasora Health Limited (“Vitasora” or the “Company”) is pleased to advise that it has now received the cornerstone investment in full, completing the A\$11 million capital raise announced earlier in the year.

Subsequent to the September 2025 quarter end and as of today, the Company received the cash from the previously announced A\$6.75 million (US\$4.5 million) cornerstone investment, issued at the placement price of \$0.03 per share. This follows the receipt of A\$3.7 million during the September 2025 quarter from a strategic placement to new and existing investors. In addition, the Company received a further commitment of \$100,000 from Nicholas Smedley and Marjan Mikel, which is subject to shareholder approval.

With the receipt of these funds, the A\$11 million capital raise has now been completed in full, with all committed funds received. The final issue of shares for this Placement will be issued over the coming days.

Strengthened Balance Sheet and Funding Outlook

The completion of the capital raise materially strengthens Vitasora’s balance sheet and provides the Company with a solid funding position to support execution of its U.S. growth strategy.

Based on current operating plans, contracted programs and the expected ramp-up of recently announced Medicaid and fee-for-service initiatives, the Board believes the Company is well positioned to reach cash flow breakeven by the end of FY2026.

The strengthened capital position provides flexibility to:

- Maintain disciplined investment in automation, AI-enabled enrolment and operational efficiency initiatives
- Support continued scaling of Connected Care programs across existing and newly signed U.S. clients
- Fund the ramp-up of high-volume Medicaid and fee-for-service programs, including Iris Health, Tampa Family Health Centers and Family Care (West Virginia)
- Manage normal timing variations associated with U.S. billing and reimbursement cycles

Operational Momentum

As outlined in the Company’s most recent Appendix 4C, operational progress during the September quarter included:

- Active patient programs increased to **22,458, up 7.6% quarter-on-quarter**, despite the conclusion of a legacy client contract



- **Iris Medical Group (IMG):** Partnership with a leading in-home care provider managing over 12,000 patients across the southeastern United States. Since commencement, approximately 1,000 patient programs have already been enrolled since late November and December, with enrolment activity ongoing. Revenue impacts are expected to be fully realised in the March quarter, reflecting standard CPT code qualification requirements (including minimum 30-day participation) and the time required to engage, consent, enrol and intake patients under normal reimbursement protocols
- **Expansion of Tampa Family Health Centers** to include both Medicare and Medicaid Chronic Care Management (CCM) and Remote Patient Monitoring (RPM) services, targeting approximately 7,000 patients
- **Strong enrolment performance** in Family Care (West Virginia), with 1,700 patients onboarded during the quarter under the enhanced enrolment and engagement framework
- Continued rollout and scaling across TPAC, Care Alliance and other fee-for-service programs
- **Sales pipeline opportunities:** The Company continues to progress a number of advanced discussions with US healthcare provider groups and care networks. These opportunities reflect growing demand for Vitasora's Connected Care services.

Outlook

Vitasora enters the 2026 with:

- A fully completed A\$11 million capital raise
- A strengthened balance sheet
- Expanding contracted program opportunities across Medicare and Medicaid fee-for-service models
- Improving enrolment conversion, scalability and operating leverage

The Board remains confident that the Company is well funded to execute its strategy and progress toward forecast cash flow breakeven by the end of FY2026, while continuing to build a scalable and sustainable Connected Care platform in the U.S. market.

– ENDS –

For further information, please contact:

For further information, investors and media please contact:

Mr Marjan Mikel

CEO & Managing Director

Vitasora Health Limited

P: +61 408 462 873

E: marjan@vitasorahealth.com

Mr Nicholas Smedley

Non-Executive Chairman

Vitasora Health Limited

P: +61 447 074 160

E: nicholas@vitasorahealth.com

This ASX announcement has been authorised for release by the Board of Directors of Vitasora Health Limited.

About Vitasora Health Limited – A Revolutionary Remote Healthcare Solutions Provider

Vitasora Health Limited (ASX:VHL, OTCQB:RSHUF) is redefining digital Connected Care in the U.S. healthcare market. We combine cutting-edge technologies and expert clinical teams to deliver a turnkey solution for providers. Our remote patient monitoring (RPM) and chronic care management (CCM) services improve outcomes, reduce costs, and help healthcare clients thrive in a value-based world.



Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We are revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Connected Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at www.vitasorahealth.com.au

About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Vitasora, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respi™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respiri.co/us/> or for [wheezo®](#)

Vitasora Health Limited is headquartered in Melbourne with offices in Los Angeles.

wheezo® is a registered trademark of Vitasora Health Limited

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Vitasora's current expectations, estimates and projections about the industry in which Vitasora operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Vitasora, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Vitasora cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Vitasora only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Vitasora will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.